運動禁藥－缺氧誘導因子穩定劑

Doping: Hypoxia-Inducible Factor Stabilizers

10.6223/qcpe.2702.201306.0905

吳睿兒(Ruei-Er Wu)；許美智(Mei-Ch Hsu)

紅血球生成刺激劑 ； 胜肽性荷爾蒙 ； 缺氧誘導因子穩定劑 ； erythropoiesis-stimulating agents ； peptide hormones ； HIFs

中華體育季刊

27卷2期（2013 / 06 / 01）

137 - 144

繁體中文

紅血球生成刺激劑可使紅血球增加，隨著基因工程技術的進步，紅血球生成素的種類漸增，而以基因重組製造之人類紅血球生成素在臨床上主要是用來治療腎衰竭和許多因其他疾病所引起的貧血。不過濫用會有副作用產生，例如：紅血球發育不良症、中風、心臟衰竭等。由於紅血球生成刺激劑（ESA）具有顯著提昇有氧能力之效果，於運動競賽中使用會導致不公平情形，因此被世界運動禁藥管制機構（WADA）列為禁用物質。伴隨著檢測技術的進步，發現使用口服的缺氧誘導因子穩定劑（HIFs）後會增加血液中血紅蛋白的含量，故WADA在2011年的禁用清單上也將缺氧誘導因子穩定劑列為「胜肽性荷爾蒙、增長因子及其相關物質項-紅血球生成刺激劑類」之運動禁藥。本文將對缺氧誘導因子穩定劑的特性和臨床用途作介紹，並探討其在運動界被禁用的原因與檢測方法。

Erythropoiesis-stimulating agents (ESAs) can increase the number of erythrocytes. Since the advance of genetic engineering enables scientists to create a series of medical products, there are several ESAs currently available such as recombinant human erythropoietin (rEPO). In addition, rEPO has been shown significantly to facilitate the management of anemia of renal failure or other diseases. However, the abuse of rEPO causes the risk of pure red cell aplasia, stroke, and cardiac failure, etc. Due to athletes may use ESAs to improve the oxygen delivery to muscles, which directly improves their endurance capacities. The rEPO is prohibited both in and out of competition on the World Anti-Doping Agency (WADA) Code Prohibited List. Hypoxia-inducible factor stabilizers (HIFs) can activates erythropoietin and increase the concentration of blood hemoglobin and elevate the capacity of oxygen delivery. HIFs are prohibited under the category of ”Peptide hormones, growth factors and related substances” on the ”2011 Prohibited List” of WADA. The current development and usage of HIFs and related small-molecule inhibitors, as well as the advanced technology platform for detection of these doping agents will be reviewed by this article.

1. 曾貞毓、許美智(2007)。運動禁藥─紅血球生成素檢測方法之探討。大專體育，2，27-30。
   連結：
2. Fibrogen Inc. (2011) FibroGen announces initiation of phase 2b studies of FG-4592, an oral HIF prolyl hydroxylase inhibitor, for treatment of anemia in chronic kidney Disease. FibroGen, News, Retrieved from: http://www.fibrogen.com
3. Armstrong, D. J.,Reilly, T.(1996).Drug in Sport (2nd Ed).London:Mottram.
4. Besarab, A.,Hulter, H. N.,Klaus, S.,Lee, T. T.,Lilienfeld, D. E.,Neff, T.,Yu, P. K.(2010).A novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients.Journal of the American Society of Nephrology,21,95A.
5. Beuck, S.,Bornatsch, W.,Lagojda, A.,Schänzer, W.,Thevis, M.(2011).Development of liquid chromatography-tandem mass spectrometrybased analytical assays for the determination of HIF stabilizers in preventive doping research.Drug Testing and Analysis,3,756-770.
6. Beuck, S.,Schänzer, W.,Thevis, M.(2012).Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis.Drug Testing and Analysis,4,830-845.
7. Beuck, S.,Schwabe, T.,Grimme, S.,Schlörer, N.,Kamber, M.,Schänzer, W.,Thevis, M.(2009).Unusual mass spectrometric dissociation pathway of protonated isoquinoline -3-carboxamides due to multiple reversible water adduct formation in the gas phase.Journal of the American Society for Mass Spectrometry,20,2034-2048.
8. Borrione, P.,Mastrone, A.,Salvo, R. A.,Spaccamiglio, A.,Grasso, L.,Angeli, A.(2008).Oxygen delivery enhancers: Past, present, and future.Journal of Endocrinological Investigation,31,185-192.
9. Bruick, R. K.,McKnight, S. L.(2001).A conserved family of prolyl-4-hydroxylases that modify HIF.Science,294,1337-1340.
10. Cooper, C. E.(2008).The biochemistry of drugs and doping methods used to enhance aerobic sport performance.Essays in biochemistry,44,63-83.
11. Egrie, J. C.,Browne, J. K.(2001).Development and characterization of novel erythropoiesisstimulating protein (NESP).Nephrology Dialysis Transplantation,16,3-13.
12. Elliott, S.,Lorenzini, T.,Chang, D.,Barzilay, J.,Delorme, E.(1997).Mapping of the active site of recombinant human erythropoietin.Blood,89,493-502.
13. Erslev, A.(1953).Humoral regulation of red cell production.Blood,8,349-357.
14. Fan, Q.,Leuther, K. K.,Holmes, C. P.,Fong, K.L.,Zhang, J.,Velkovska, S.,Woodburn, K.W.(2006).Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.Experimental Hematology,34,1303-1311.
15. Kochendoerfer, G.(2003).Protein & Peptide Drug Delivery (3rd Ed).USA, CA:Gryphon Therapeutics.
16. Lee, J. W.,Bae, S. H.,Jeong, J. W.,Kim, S. H.,Kim, K. W.(2004).Hypoxia-inducible gfactor (HIF-1) alpha: Its protein stability and biological functions.Experimental and Molecular Medicine,36,1-12.
17. Macdougall, I. C.(2008).Hematide, a novel peptidebased erythropoiesis-stimulating agent for the treatment of anemia.Current opinion in investigational drugs,9,1034-1047.
18. Macdougall, I. C.,Ashenden, M.(2009).Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.Advances in Chronic Kidney Disease,16,117-30.
19. Macdougall, I. C.,Rossert, J.,Casadevall, N.,Stead, R. B.,Duliege, A. M.,Froissart, M.,Eckardt, K.U.(2009).A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.The New England Journal of Medicine,361,1848-1855.
20. Michiels, C.(2004).Physiological and pathological responses to hypoxia.American Journal of Pathology,164,1875-1882.
21. Minchenko, A.,Leshchinsky, I.,Opentanova, I.,Sang, N.,Srinivas, V.,Armstead, V.,Caro, J.(2002).Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/ fructose-2, 6-bisphosphatase-3 (PFKFB3) gene: Its possible role in the Warburg effect.Journal of Biological Chemistry,277,6183-6187.
22. Panchapakesan, U.,Sumual, S.,Pollock, C.(2007).Nanomedicines in the treatment of anemia in renal disease: Focus on CERA (Continuous Erythropoietin Receptor Activator).International Journal of Nanomedicine,2,33-38.
23. Philipp, S.,Jürgensen, J. S.,Fielitz, J.,Bernhardt, W. M.,Weidemann, A.,Schiche, A.,Willenbrock, R.(2006).Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats.European Journal of Heart Failure,8,347-354.
24. Schwandt, H. J.,Heyduck, B.,Gunga, H. C.,Röcker, L.(1991).Influence of prolonged physical exercise on the erythropoietin concentration in blood.European Journal of Applied Physiology and Occupational Physiology,63,463-466.
25. Semenza, G. L.,Wang G. L.(1992).A nuclear factor induced by hypoxia via de novo proteinsynthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.Molecular and Cellular Biology,12,5447-5454.
26. Stead, R. B.,Lambert, J.,Wessels, D.,Iwashita, J. S.,Leuther, K. K.,Woodburn, K. W.,Duliege, A. M.(2006).Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase I, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.Blood,108,1830-1834.
27. Takeuchi, M.,Kobata, A.(1991).Structures and functional roles of the sugar chains of human erythropoietins.Glycobiology,1,337-346.
28. Tanaka, T.,Nangaku, M.(2009).Drug discovery for overcoming chronic kidney disease (CKD): Prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD.Journal of Pharmacological Sciences,109,24-31.
29. Tarng, D. C.(2007).Cardiorenal anemia syndrome in chronic kidney disease.Journal of the Chinese Medical Association,70,424-429.
30. Thevis, M.,Kohler, M.,Schlörer, N.,Schänzer, W.(2008).Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation.Journal of the American Society for Mass Spectrometry,19,151-158.
31. Woodburn, J. D.,Smith, K. L.,Nelson, G. D.(2007).Quality of care in the retail health care setting using national clinical guidelines for acute pharyngitis.American Journal of Medical Quality,22,457-462.
32. Yan, L.,Colandrea, V. J.,Hale, J. J.(2010).Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: Small molecule-based therapeutics for anemia.Expert Opinion on Therapeutic Patents, Informa Healthcare,20,1219-1245.
33. 許嫚真、詹貴惠(2011)。運動禁藥之紅血球生成刺激劑。臺灣體育論壇，2，23-32。
34. 楊富鈞、林秉熙(2009)。紅血球生成刺激劑的比較。腎臟與透析，21，118-221。